The FDA's Peptide Moment: What the 503A Bulks List Actually Is and Why July 2026 Matters

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee meets at the White Oak Campus in Silver Spring, Maryland to review seven peptides for potential inclusion on the 503A Bulk Drug Substances List. If you follow the peptide space at all, you have seen this covered. What is less well covered is what the list actually is, how these seven peptides ended up in front of the committee in the first place, and what actually changes if the vote goes the way many in the community are hoping.

The answer to that last question is: less than most headlines suggest, and faster than the regulatory process usually allows only if RFK Jr. decides to take an unusual step.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding pharmacies. These are pharmacies that prepare individualised medications for specific patients, typically for cases where a commercially available product does not meet a patient's needs, such as a patient who needs a different dose than what is manufactured, or who requires a formulation without a specific allergen.

Under 503A, compounding pharmacies can prepare medications using bulk drug substances only if those substances appear on the 503A Bulk Drug Substances List. This is sometimes called the "Category 1 list." Category 1 means the substance is cleared for use in licensed compounding.

Category 2 is different. It is a holding category for substances the FDA has flagged as raising significant safety concerns. A substance in Category 2 cannot legally be used in 503A compounding. It is effectively prohibited from the compounding pathway until the FDA acts to move it or clear it.

Before either Category 1 or Category 2 existed in any formal sense, many peptides existed in a grey area: not approved drugs, not listed as prohibited, simply unaddressed by the system. Compounding pharmacies operated in that grey space for years.

In September 2023, the FDA moved more than a dozen peptides into Category 2, citing "significant safety concerns." The cited concerns included immunogenicity risk, impurity concerns, and the fact that human clinical data for most of these peptides was limited to small studies or absent entirely.

The compounds placed into Category 2 in 2023 included BPC-157, TB-500, Ipamorelin, CJC-1295, Thymosin Alpha-1, AOD-9604, and others. This did not make them illegal to possess or purchase as research compounds. It did effectively shut down the compounding pharmacy pathway, which had been the most medically supervised and quality-controlled access route for these compounds in the US market.

The result was predictable. Demand did not go away. It shifted toward online research peptide vendors operating under the research-use-only designation, with considerably less oversight than a licensed compounding pharmacy.

Two things changed the trajectory. First, an FDA lawsuit. The clinic Evexias Medical Centers and the pharmacy Farmakeio filed suit in Texas under the Administrative Procedure Act, arguing that the FDA had acted without adequate transparency in placing certain peptides in Category 2. The suit specifically targeted four compounds: AOD-9604, CJC-1295, Ipamorelin, and Thymosin Alpha-1.

Second, and more publicly visible, was RFK Jr. As HHS Secretary, Kennedy has been vocal about reversing the 2023 categorisation, framing it on his X account and in media appearances as a policy that "created a black market." He discussed the issue on Joe Rogan's podcast, where his son provided him with breaking regulatory news in real time, according to the FDA Law Blog's characteristically wry account of events.

On April 16, 2026, the FDA published a Federal Register notice announcing two things. First, it was removing 12 peptides from Category 2 within seven calendar days. Second, it was scheduling a PCAC meeting to formally review seven of those peptides for potential Category 1 status.

The 12 peptides removed from Category 2 included the seven being reviewed at the July meeting plus five additional compounds that will be reviewed at a second PCAC meeting before February 2027: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated.

Day one, July 23rd: BPC-157 (both free base and acetate forms), KPV, TB-500, and MOTS-C.

Day two, July 24th: Emideltide (also called Delta Sleep-Inducing Peptide or DSIP), Semax, and Epitalon.

Each is being reviewed for specific proposed indications. BPC-157 for ulcerative colitis and wound healing. TB-500 for musculoskeletal repair. Semax for cognitive support and cerebral ischemia. Epitalon for its research profile in longevity and sleep.

The PCAC will hear evidence, accept public comments, and vote on whether to recommend these substances for Category 1.

This is the part that gets underreported.

A PCAC recommendation is advisory. It is not binding on the FDA. Even if every committee member votes to recommend Category 1 status for all seven peptides, the FDA is under no legal obligation to act immediately.

The standard pathway from PCAC recommendation to formal Category 1 status requires notice-and-comment rulemaking. This process, in which the FDA publishes a proposed rule, accepts public comment, reviews comments, and publishes a final rule, typically takes more than a year under normal conditions. Given that the 503A bulks list rulemaking process has historically moved slowly, with only around ten substances having gone through a final rule since the relevant legislation passed in 2013, the timeline could be considerably longer.

Removal from Category 2 is not the same as placement in Category 1. The compounds removed from Category 2 in April 2026 are now in a regulatory grey area. They are not prohibited from compounding, but they are not cleared for it either. Legal risk for compounding pharmacies operating in this space remains.

There is one possible shortcut. Section 503A(c) of the relevant statute allows the Secretary to bypass the advisory committee consultation if doing so is necessary to protect the public health. Some legal analysts have noted that RFK Jr. could theoretically use this provision to place these peptides directly into Category 1 as an emergency measure, framing the existing grey market as the public health threat that justifies expedited action. Whether he chooses to do this, and whether it would survive legal challenge, is an open question.

For people in the US currently accessing these peptides through research vendors: nothing changes immediately. The removal from Category 2 does not confer legal human-use status. It does, however, signal clear political will toward eventual regulated access and reduces the regulatory hostility that had been building since 2023.

For compounding pharmacies: the picture is murky. Some attorneys advise that compounders can now operate in this space with reduced legal risk given the Category 2 removal, but formal Category 1 status has not been granted.

For everyone watching this space: the July 23-24 meeting is worth following. Public comments are accepted until July 22nd via docket FDA-2025-N-6895. The outcome shapes whether compounds like BPC-157 and TB-500 eventually have a legitimate, medically supervised pathway in the US, or whether demand continues to be served by the largely unregulated research market.

The direction of travel is clear. The speed of arrival is not.

This article is for educational purposes only and does not constitute legal or medical advice. Regulatory status of peptides changes. Consult qualified professionals and verify current legal status in your jurisdiction before making any decisions.